Retatrutide

Overview

Retatrutide (development code LY3437943) is an investigational peptide drug developed by Eli Lilly. It is engineered to activate three metabolic receptors at once: the GIP (glucose-dependent insulinotropic polypeptide) receptor, the GLP-1 (glucagon-like peptide-1) receptor, and the glucagon receptor. Because of this it is often described as a triple agonist or "triple-G" agonist. It has been studied in clinical trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD).

Chemistry and structure

Retatrutide is a synthetic peptide built on an incretin-hormone backbone of roughly 39 amino acids, modified with a fatty-acid (lipid) side chain. This lipidation promotes binding to albumin in the bloodstream, which slows clearance and gives the molecule a long duration of action, the basis for its once-weekly subcutaneous dosing schedule studied in trials.

The molecule was rationally designed to engage all three target receptors with differing potencies. Its reported molecular weight is approximately 4,731 Da, though values reported by chemical vendors vary with salt form and source, and the exact amino-acid sequence is proprietary to Eli Lilly. The assigned CAS registry number is 2381089-83-2.

Mechanism of action (triple agonism)

Most approved incretin drugs target one or two receptors: semaglutide is a single GLP-1 agonist, and tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds a third target — the glucagon receptor — to the GIP and GLP-1 pathways.

• GLP-1 receptor agonism reduces appetite and food intake, slows gastric emptying, and enhances glucose-dependent insulin secretion.
• GIP receptor agonism contributes to insulin secretion and is thought to add to the appetite and metabolic effects seen with GLP-1.
• Glucagon receptor agonism is the distinguishing feature. While glucagon can raise blood glucose, it is also associated with increased energy expenditure, enhanced lipolysis (fat breakdown), and reduced liver fat. The concurrent GLP-1 and GIP activity is thought to offset glucagon's glucose-raising tendency, so that net glycemic control is preserved or improved while the added energy-expenditure and hepatic-fat effects of glucagon agonism are harnessed.

The rationale for triple agonism is that combining appetite suppression (GLP-1/GIP) with increased energy expenditure and fat mobilization (glucagon) may produce greater weight loss and metabolic benefit than single- or dual-receptor agents. This remains a hypothesis supported by trial data rather than a settled clinical conclusion.

Clinical trials and evidence

Phase 2 obesity trial (Jastreboff et al., NEJM 2023)

A 48-week, randomized, double-blind, placebo-controlled phase 2 trial enrolled 338 adults with obesity. Participants received once-weekly retatrutide at escalating maintenance doses (1, 4, 8, or 12 mg) or placebo. Weight loss was dose-dependent, and the trial authors reported that weight reduction continued through week 48 with no plateau observed at the highest doses.

Source: Jastreboff AM et al., N Engl J Med 2023;389(6):514-526.

Phase 2 diabetes trial (Rosenstock et al., Lancet 2023)

A 36-week (24-week primary endpoint) randomized, double-blind, placebo- and active-comparator-controlled phase 2 trial studied retatrutide in adults with type 2 diabetes (the active comparator was dulaglutide 1.5 mg). Retatrutide produced dose-dependent reductions in HbA1c and body weight.

Source: Rosenstock J et al., Lancet 2023;402(10401):529-544.

Liver disease (MASLD) phase 2a (Sanyal et al., Nature Medicine 2024)

In a phase 2a substudy, retatrutide produced large reductions in liver fat; the authors reported that a majority of participants at higher doses achieved resolution of hepatic steatosis (defined as less than 5% liver fat) by 24 weeks.

Phase 3 (TRIUMPH program)

Retatrutide advanced into a large phase 3 program named TRIUMPH, comprising multiple pivotal trials across obesity, obesity with comorbidities (including knee osteoarthritis, cardiovascular disease, and type 2 diabetes), plus a dedicated cardiovascular-outcomes trial.

The first pivotal phase 3 readout, TRIUMPH-1 (NCT05929066), was reported by Eli Lilly on May 21, 2026. In adults with obesity or overweight and at least one weight-related complication (without diabetes), all three doses met the primary and key secondary weight-loss endpoints over 80 weeks.

Source: Eli Lilly press release, May 21, 2026 (TRIUMPH-1; NCT05929066). In an extension to 104 weeks, the 12 mg group reportedly reached ≈30.3% (≈85 lb).

Strength of evidence: The obesity and diabetes phase 2 trials are peer-reviewed and published in high-quality journals (NEJM, Lancet). The phase 3 TRIUMPH-1 results are, as of June 2026, primarily available through a company press release; full peer-reviewed publication and additional TRIUMPH trials (diabetes, cardiovascular) were still anticipated. Press-release figures should be regarded as preliminary until the corresponding peer-reviewed papers appear.

Safety and reported effects

Across trials, the reported safety profile was broadly consistent with other incretin-based therapies, dominated by gastrointestinal effects that were generally dose-dependent and most common during dose escalation:

• Nausea, diarrhea, vomiting, and constipation were the most frequently reported adverse events, increasing with dose.
• Heart-rate changes: In the phase 2 obesity trial, modest dose-dependent increases in heart rate were observed (on the order of several beats per minute at higher doses), peaking around week 24 and then declining. Glucagon and GLP-1 can exert positive chronotropic effects on the heart, which is the proposed explanation.
• Some trials reported skin sensation changes (e.g., dysesthesia) at higher doses in the phase 3 obesity readout.

As with all investigational agents, the complete long-term safety and efficacy profile is not yet established, and rare or delayed risks may only become apparent with larger and longer studies. The class-wide labeled warnings for approved GLP-1 and GIP/GLP-1 drugs (such as gastrointestinal effects and, for the class, monitoring considerations) provide useful context but are not a substitute for retatrutide's own eventual regulatory labeling.

Regulatory status

As of June 2026, retatrutide is not approved for any use by the FDA, the EMA, or any other regulatory authority. It remains an investigational drug in Eli Lilly's phase 3 program. A regulatory submission timeline had not been definitively confirmed in public sources at the time of writing; commentary anticipating a filing or approval in 2026–2028 is speculative and should not be treated as established fact.

How it compares

Retatrutide belongs to the incretin-based weight-loss class and is best understood against the two approved drugs in this category:

• Semaglutide, an approved GLP-1 receptor agonist (Ozempic/Wegovy) with extensive trial and real-world data.
• Tirzepatide, an approved dual GIP/GLP-1 agonist (Mounjaro/Zepbound).

Retatrutide adds a third target (glucagon) and reported large weight reductions in phase-2 and phase-3 trials. The decisive difference, however, is regulatory: semaglutide and tirzepatide are approved; retatrutide is not — it remains investigational and available only within clinical trials. For an approved, evidence-backed option today the data point to the two licensed drugs; retatrutide's promise is real but not yet established by a completed approval. See the Weight management overview.

Common misconceptions and unregulated-source warning

• "Retatrutide is FDA approved / available by prescription." It is not. Approved options in the same broad class include semaglutide (GLP-1) and tirzepatide (GIP/GLP-1); retatrutide is distinct and still investigational.
• "Trial doses are a usage protocol." The doses described above are reported factually from past trials for educational completeness. They are not a how-to and do not constitute medical advice or a dosing recommendation.
• "Glucagon agonism just raises blood sugar." In retatrutide, glucagon-receptor activity is combined with GLP-1/GIP activity; in trials, net glycemic control improved while the energy-expenditure and liver-fat effects of glucagon agonism were pursued. The balance among receptors is central to the drug's design.

---

This entry is educational and summarizes published trial data and public regulatory information. It is not medical advice, a recommendation, or a guide to obtaining or using any substance. Investigational drugs should only be used within an authorized clinical trial under medical supervision.

Community claims & recent evidence

The points below address claims circulating in the peptide community — including popular video "masterclasses" — checked against primary sources. Such talks mix real data with confident-sounding pseudo-citations and with trials that actually belong to other drugs; only claims that resolve to a real primary source are kept here.

Verified additions

• Half-life ≈6 days. Retatrutide's elimination half-life is approximately 6 days, which is what makes once-weekly subcutaneous dosing feasible and means steady-state is only reached after roughly 4 weeks of dosing. [Human] (Urva S et al., The Lancet 2022;400:1869–1881.)
• Body composition — fat is lost preferentially, but muscle is not uniquely spared. In a DXA substudy of the phase 2 type-2-diabetes trial, retatrutide reduced total fat mass dose-dependently (up to ≈26% at 8 mg over 36 weeks) and reduced android/visceral fat, outperforming both placebo and dulaglutide. Crucially, the proportion of lean mass lost relative to total weight loss was similar to other incretin therapies — not lower. [Human] (Coskun T et al., Lancet Diabetes & Endocrinology 2025;13:674–684.)

Claims that don't hold up

• "The dose-response plateaus at 4–8 mg, so 8 mg (≈18%) is barely better than 4 mg (≈17.5%)." This contradicts the published trial. In the phase 2 obesity trial, weight loss was dose-dependent with no plateau at the highest doses: mean loss reached −24.2% at 12 mg by week 48 and was still ongoing. The specific plateau figures cited do not match the NEJM data. [Human] (Jastreboff AM et al., N Engl J Med 2023;389:514–526.)
• "The SELECT trial showed retatrutide cut major cardiovascular events by 20%." Misattributed. SELECT is a semaglutide cardiovascular-outcomes trial (17,604 patients), not retatrutide. Retatrutide's own cardiovascular-outcomes trial was still underway and unreported at the time. [Human] (Lincoff AM et al., N Engl J Med 2023;389:2221–2232.)
• "The FLOW trial showed retatrutide slowed kidney-disease progression by 24%." Misattributed. FLOW is a semaglutide kidney-outcomes trial; the 24% risk reduction is semaglutide's, not retatrutide's. [Human] (Perkovic V et al., N Engl J Med 2024;391:109–121.)
• "SURMOUNT trials in ~5,000 patients proved retatrutide causes zero medullary thyroid cancer." Misattributed. SURMOUNT is the tirzepatide program, not retatrutide. The rodent thyroid C-cell signal is a GLP-1-class labeling issue; the human reassurance data invoked belong to other drugs, and retatrutide's own long-term cancer safety is not yet established. [Human/Animal]
• "Retatrutide needs 100–200 g of carbohydrate a day; keto/low-carb 'tanks' it (a 2022 JCEM study showed 40% greater efficacy with carbs)." No such study exists. No retatrutide trial has tested dietary carbohydrate as a modifier of its effect; the fact that the incretin insulin response is glucose-dependent does not mean the drug's weight-loss or glucagon effects require dietary carbs. The cited statistic resolves to no real retatrutide paper. [Hypothesis]
• "Retatrutide is the only one that spares muscle / ~78% of the loss is fat, unlike semaglutide or tirzepatide." Overstated. The DXA substudy above found the lean-to-total loss ratio similar to other incretin drugs, not uniquely favourable. Broader percentage claims in the talk (e.g. specific "Cell Metabolism," "Cell Reports," or "Neurology" figures for ATP production, brain inflammation, or neuroprotection) attribute class-level or animal mechanistic findings to retatrutide and do not trace to a retatrutide human primary source. [Human]

Combinations and interactions

The community — largely via popular "combined playbook"-style stacking videos — discusses stacking Retatrutide with several other compounds. This section explains what the evidence does and does not show for each pairing. It is a research reference, not a protocol, and contains no dosing, timing, or titration guidance. For essentially every combination below, the honest finding is the same: there is no controlled human data on the combination itself.

Retatrutide + Tesamorelin

Tesamorelin is a GHRH analog, and the community rationale pairs it with retatrutide on the idea that a growth-hormone rise preserves or adds lean mass and targets visceral fat while retatrutide drives overall weight loss. There is no controlled human data on this combination: retatrutide's obesity results come only from single-agent phase 2 trials (~24% mean weight loss at 48 weeks) [Human], while tesamorelin is FDA-approved solely for reducing visceral adipose tissue in HIV-associated lipodystrophy and was never studied with an incretin agonist [Human] — the "lean-mass preservation" rationale for the stack is unverified [Hypothesis]. Pharmacologically the two work against each other on glucose: tesamorelin raises GH/IGF-1, which reduces insulin sensitivity and can increase blood glucose and HbA1c [Human], directly counteracting retatrutide's metabolic aim and confounding glucose monitoring. Adding a second injectable also compounds retatrutide's dose-dependent GI burden (nausea, vomiting, diarrhea, dehydration) [Human] with tesamorelin-specific hazards — fluid retention, arthralgia/peripheral edema, injection-site reactions, and contraindication in active malignancy (the GH/IGF-1 axis is mitogenic) and pregnancy [Human/label] — for no demonstrated added benefit.

Retatrutide + Tirzepatide

Combining two incretin agonists adds toxicity risk without proven added benefit — do not read this as an endorsement — even stacking-focused videos warn against this specific pairing, and the pharmacology agrees. Retatrutide and Tirzepatide hit the SAME receptors (both activate GLP-1R and GIP-R; retatrutide additionally activates glucagon-R), so stacking them is additive agonism at overlapping targets rather than a new mechanism [Hypothesis grounded in shared pharmacology]. There is no controlled human data on the combination — no trial has evaluated coadministration — and the Zepbound (tirzepatide) label notes that concomitant use with other GLP-1 receptor agonists has not been studied [Human/label]. The expected result is amplified toxicity: additive GI effects (nausea, vomiting, diarrhea) that are dose-dependent for both and raise the risk of severe dehydration and pre-renal/acute kidney injury, additive appetite/energy suppression with meaningful hypoglycemia risk if either is used with insulin or a sulfonylurea, and overlapping class warnings — tirzepatide carries a boxed warning for thyroid C-cell (medullary) tumors seen in rodents and is contraindicated in personal/family history of MTC or MEN2 [Animal/label], while pancreatitis and gallbladder signals overlap between the two [Human].

Retatrutide + Cardarine (GW-501516)

The community frames Cardarine, a PPARδ agonist marketed as an "exercise mimetic," as an endurance and body-recomposition add-on to retatrutide's weight loss. This is the pairing where the partner compound carries the most serious documented hazard on its own: GW-501516 induced tumors across multiple organ systems in 2-year (104-week) carcinogenicity studies in rats and mice, which is why GSK/Ligand halted development [Animal] — a documented cancer signal, not a theoretical one. There is no controlled human data on the combination, and cardarine has no completed human efficacy or safety trials at all (no established PK, no human toxicology, no dosing basis) [Animal/In vitro]; retatrutide's data are single-agent human [Human], so the pair is entirely untested in people. Cardarine is also WADA-prohibited in and out of competition since 2009 (an automatic anti-doping rule violation for any tested athlete), and there is a plausible additive hepatic concern: retatrutide's glucagon-receptor agonism increases hepatic metabolic workload [Human/mechanism] while cardarine is hepatically active with a documented hepatotoxicity case when misused alongside a SARM [Human case report]. Both are supplied only as research chemicals with no pharmacopeial identity or purity standard.

Retatrutide + 5-Amino-1MQ

5-Amino-1MQ is an NNMT inhibitor framed by the community as an additive adipose/metabolic fat-loss partner to retatrutide. There is no controlled human data on the combination — and no published human data on 5-Amino-1MQ at all: its adipocyte and weight effects come only from 3T3-L1 cell cultures [In vitro] and diet-induced-obesity mouse models [Animal], while retatrutide's data are single-agent human [Human]. The pair has never been tested together in any species reported in the literature [Hypothesis]. Because NNMT is broadly expressed (liver, adipose, kidney) and 5-Amino-1MQ has no published human PK, toxicology, or dosing data, the systemic and off-target consequences of inhibiting it in humans are simply unknown; both agents also push the same fat-loss endpoint, so any adverse event could not be reliably attributed to either, and the overlap compounds retatrutide's already dose-limiting GI/dehydration burden [Human] with no demonstrated added benefit. It is supplied only as a research chemical with no verifiable identity or purity standard.

This is research context only — not medical advice and not a protocol. No combination here is endorsed, dosed, or shown to be safe or effective; every pairing lacks controlled human data on the combination itself.

Frequently asked questions

Does a higher dose of retatrutide really work better than "microdosing"?

In the phase 2 obesity trial, weight loss was dose-dependent — higher maintenance doses produced more weight loss, not less, with mean loss reaching −24.2% at 12 mg by week 48 and no plateau at the top dose. [Human] (Jastreboff AM et al., N Engl J Med 2023;389:514–526.) So the popular framing that "more doesn't mean better," or that a very low "microdose" matches full doses, is not what the trial data show. However, gastrointestinal side effects (nausea, diarrhoea, vomiting) also rose with dose, which is why trials escalated slowly — efficacy and side-effect burden move together. This page reports trial doses factually and is not a dosing recommendation.

Does retatrutide damage your liver?

The available human evidence points the opposite way. In a phase 2a trial in metabolic dysfunction-associated steatotic liver disease (MASLD), retatrutide produced large reductions in liver fat, and a majority of participants at higher doses reached resolution of hepatic steatosis (<5% liver fat) by 24 weeks. [Human] (Sanyal AJ et al., Nat Med 2024.) No signal of drug-induced liver injury has been reported in the published trials, and there is no evidence that "megadosing" versus "microdosing" damages the liver differently — that framing does not come from the trial data. Long-term safety is still not fully established.

What should you do if retatrutide seems to "stop working"?

There is no published evidence that retatrutide develops tolerance or "stops working," and no validated lab protocol for that scenario exists. [Human] A slowing of weight loss over time is expected physiology as the body reaches a new energy balance, not necessarily a sign the drug has failed — in the phase 2 obesity trial, weight loss was still ongoing at 48 weeks at the highest dose. [Human] Claims about specific labs to run and fixes to apply do not trace to a primary source, and this page cannot give protocol or medical advice; clinical decisions belong with a physician in a supervised setting.

Do you have to take retatrutide forever?

Retatrutide itself has not been studied for what happens after you stop, so there is no retatrutide-specific answer yet. [Human] For approved drugs in the same class, discontinuation has been followed by substantial weight regain: participants in the semaglutide STEP 1 extension regained about two-thirds of the lost weight within a year of stopping (Wilding JPH et al., Diabetes Obes Metab 2022), and the tirzepatide SURMOUNT-4 trial showed weight regain after switching to placebo (Aronne LJ et al., JAMA 2024). [Human] Whether retatrutide behaves the same way is a reasonable hypothesis but not yet demonstrated. [Hypothesis]

Is retatrutide an anti-aging drug or a "weapon against aging"?

No. Retatrutide has been studied for obesity, type 2 diabetes, and fatty liver disease — not for longevity or aging — and no human trial has shown it slows aging. [Human] Claims that it is a "weapon against aging" are hypotheses extrapolated from its metabolic effects (weight, liver fat, cardiometabolic risk factors), not findings from any aging endpoint. [Hypothesis] Improving metabolic health is not the same as reversing or slowing biological aging, and that leap is unproven.

Can retatrutide be combined with Cardarine (GW-501516)?

There is no research on combining retatrutide with cardarine — no trial has tested that pairing, so any claimed benefit or safety is unproven. [Hypothesis] Cardarine itself was never approved: its development was halted after animal studies showed it caused cancer across multiple organs. [Animal] Stacking an investigational drug with an abandoned experimental compound that carries an animal carcinogenicity signal has no evidence base, and nothing here should be read as endorsing it.

Is retatrutide actually better than semaglutide or tirzepatide for weight loss?

No head-to-head trial has directly compared retatrutide against semaglutide or tirzepatide, so "better" rests on cross-trial comparison — unreliable because trial populations and designs differ. [Human] Retatrutide's reported weight loss in its own trials is large (up to −24.2% at 12 mg by week 48 in phase 2, and −28.3% at 80 weeks in TRIUMPH-1 per Eli Lilly's press release), and it adds a third receptor target (glucagon). But semaglutide and tirzepatide are approved with mature safety data, whereas retatrutide is still investigational and available only within clinical trials. Bigger numbers on paper are not the same as a proven, approved advantage.